Atopic Dermatitis

LEO Pharma reveals promising phase 2b trial results for temtokibart, a treatment targeting moderate to severe atopic dermatitis effectively.

Explore the significant mental health and socioeconomic impacts of atopic dermatitis and alopecia areata, revealing urgent needs for better support and awareness.

Tralokinumab offers a promising alternative for patients with atopic dermatitis experiencing dupilumab-related arthralgia, achieving skin clearance and symptom relief.

Triveni Bio initiates a phase 1 trial for TRIV-509, a promising treatment for atopic dermatitis, targeting key inflammatory pathways.

Albert Chiou, MD, MBA, discusses early clinical data on soquelitinib for atopic dermatitis, highlighting its targeted ITK inhibition, dose-dependent efficacy, favorable safety profile, and more.

The study offers reassurance regarding the safety profile of JAKis in patients with severe atopic dermatitis, particularly concerning their impact on venous thromboembolic events.

Christopher Bunick, MD, PhD, discusses key differences in AD biologics and challenges in achieving optimal treatment targets.

GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.

Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.

Raj Chovatiya, MD, PhD, MSCI, discusses how IL-13 and IL-31 inhibitors represent distinct yet complementary mechanisms in the management of atopic dermatitis.

To hear more about AD advancements from Shahriari and Lio in person, register to attend the Revolutionizing Atopic Dermatitis Conference 2025 in Nashville, Tennessee, on June 6 and 7.

Christopher Bunick, MD, PhD, explains why composite endpoints are now critical for evaluating patient outcomes in AD therapy.

Discover the latest advancements in pediatric atopic dermatitis care, featuring expert insights on innovative treatments and family-centered management strategies.

Explore the evolving landscape of dermatology as experts emphasize the importance of cross-specialty collaboration and patient-centered care in aesthetic medicine.

Data from the Level Up study shows that switching from dupilumab to upadacitinib enables more patients to achieve optimal targets of skin clearance and itch relief.

Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.

Recent analysis reveals abrocitinib's long-term safety in atopic dermatitis, highlighting age-related risks and the importance of tailored dosing for older patients.

New research from AAD 2025 highlights upadacitinib's effectiveness over dupilumab for treating atopic dermatitis, especially in challenging facial and neck areas.

Researchers reported that upadacitinib may lower the incidence of major cardiovascular events and venous thromboembolism in AD.

Peter Lio, MD, discusses innovative treatments for pediatric atopic dermatitis, including microbiome therapies and botanical options.

Christopher Bunick, MD, PhD, discusses the evolving role of OX40-targeted biologics in atopic dermatitis treatment ahead of the upcoming RAD conference.

Raj Chovatiya, MD, PhD, MSCI, reviews the limitations of chronic steroid use and highlights available topicals, including ruxolitinib, roflumilast, and tapinarof.

At a recent Dermatology Times Case-Based Roundtable event, Lisa Swanson, MD, discussed 3 diverse atopic dermatitis patient cases.

New research reveals JAK inhibitors for atopic dermatitis do not increase cardiovascular or cancer risks compared to IL-4/-13 inhibitors, offering reassurance for patients.